Showing 2978 results
-
Press release /New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,…
-
Press release /Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be made available through direct-to-patient platforms in 2026Company…
-
Press release /Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1Rhapsido …
-
Press release /Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent…
-
Press release /
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentationNew Phase IIIb REMIXED… -
Press release /At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North…
-
Press release /Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali® NATALEE oral presentation to report…
-
Press release /Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of…
-
Press release /If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority…